Search results
Results from the WOW.Com Content Network
Pre-exposure prophylaxis (PrEP), is the use of medications to prevent the spread of disease in people who have not yet been exposed to a disease-causing agent. Vaccination is the most commonly used form of pre-exposure prophylaxis ; other forms of pre-exposure prophylaxis generally involve drug treatment, known as chemoprophylaxis .
No significant changes in fat redistribution or change in fat had been noted when used as a pre-exposure prophylaxis. Research and study outcome analysis suggests that emtricitabine/tenofovir does not have a significant effect on fat redistribution or accumulation when used as pre-exposure prophylaxis in HIV negative individuals. [37]
Pre-exposure prophylaxis (PrEP) provides HIV-negative individuals with medication—in conjunction with safer-sex education and regular HIV/STI screenings—in order to reduce the risk of acquiring HIV. [40] In 2011, the journal Science gave the Breakthrough of the Year award to treatment as prevention. [41]
"Pre-exposure prophylaxis" refers to the practice of taking some drugs before being exposed to HIV infection, and having a decreased chance of contracting HIV as a result of taking that drug. Post-exposure prophylaxis refers to taking some drugs quickly after being exposed to HIV, while the virus is in a person's body but before the virus has ...
The Partners PrEP (pre-exposure prophylaxis) trial was funded by the Bill & Melinda Gates Foundation [98] and conducted by the International Clinical Research Center at the University of Washington. The trial followed 4758 heterosexual couples in Kenya and Uganda, in which one individual was HIV positive and the other was HIV negative. [ 97 ]
Pages in category "Pre-exposure prophylaxis for HIV prevention" The following 4 pages are in this category, out of 4 total. This list may not reflect recent changes .
This page was last edited on 30 November 2023, at 14:24 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
According to Robert Goldstein, MD, over 1 million people at risk for HIV in the United States may benefit from pre-exposure prophylaxis (PrEP) medications, but fewer than one in four receive it. [2] To address the cost barriers to PrEP, HHS launched Ready, Set, PrEP in December 2019 with the goal of expanding access to those disproportionately ...